Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1Anophthalmia with pulmonary hypoplasia 1

Interventions

Specimen Handling 40Biopsy 32Magnetic Resonance Spectroscopy 26pembrolizumab 20Nivolumab 10trastuzumab deruxtecan 9Paclitaxel 9Carboplatin 9Radiosurgery 7Irinotecan 7Gemcitabine 7X-Rays 6Pemetrexed 6Leucovorin 6Ipilimumab 6Fulvestrant 6Fluorouracil 6Cetuximab 6Bevacizumab 6palbociclib 5Taxes 5Oxaliplatin 5Cisplatin 5Capecitabine 5130-nm albumin-bound paclitaxel 5durvalumab 4Letrozole 4CTLA-4 Antigen 4ribociclib 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × budigalimab × 30 days × Clear all
NCT06119217 2026-05-13

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Trishula Therapeutics, Inc.

Phase 2 Completed
194 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡